Nivolumab shows promise in first-ever trial for patients with refractory, metastatic anal cancer
In the first-ever clinical trial for metastatic patients previously treated for the disease, research led by The University of Texas MD Anderson Cancer Center found that the immune checkpoint blockade nivolumab shows promise for the majority of patients with squamous cell carcinoma of the anal canal (SCCA).
Go to Source
